Free Trial

Inozyme Pharma (INZY) Stock Price, News & Analysis

-0.02 (-0.43%)
(As of 05/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
311,985 shs
Average Volume
432,341 shs
Market Capitalization
$289.50 million
P/E Ratio
Dividend Yield
Price Target

Inozyme Pharma MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
263.2% Upside
$17.00 Price Target
Short Interest
8.23% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Selling Shares
$52,210 Sold Last Quarter
Proj. Earnings Growth
From ($1.59) to ($1.61) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.44 out of 5 stars

Medical Sector

667th out of 920 stocks

Pharmaceutical Preparations Industry

316th out of 431 stocks

INZY stock logo

About Inozyme Pharma Stock (NASDAQ:INZY)

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

INZY Stock Price History

INZY Stock News Headlines

Inozyme Pharma: Q4 Earnings Insights
Inozyme Pharma: Q4 Earnings Insights
See More Headlines
Receive INZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.92 per share


Free Float
Market Cap
$289.50 million
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Douglas A. Treco Ph.D. (Age 66)
    CEO & Chairman
    Comp: $77k
  • Mr. Axel Bolte M.B.A. (Age 52)
    M.Sc., Co-Founder, Senior Advisor & Director
    Comp: $1.03M
  • Mr. Sanjay S. Subramanian M.B.A. (Age 47)
    M.S., Senior VP, CFO & Principal Accounting Officer
    Comp: $726.3k
  • Dr. Demetrios Braddock M.D.
    Ph.D., Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer
  • Dr. Matthew Winton Ph.D. (Age 46)
    Senior VP & COO
  • Dr. Soojin Kim Ph.D.
    Senior VP & Chief Technical Operations Officer
  • Dr. David Thompson M.A.
    M.S., Ph.D., Senior VP, Chief Scientific Officer & Chief Development Officer
  • Mr. Stefan Riley
    Director of Investor Relations
  • Ms. Gayle Gironda
    Senior VP & Chief People Officer
  • Dr. Yves Sabbagh Ph.D.
    Chairman of Scientific Advisory Board & Senior VP

INZY Stock Analysis - Frequently Asked Questions

Should I buy or sell Inozyme Pharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inozyme Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INZY shares.
View INZY analyst ratings
or view top-rated stocks.

What is Inozyme Pharma's stock price target for 2024?

4 brokers have issued twelve-month price targets for Inozyme Pharma's stock. Their INZY share price targets range from $14.00 to $23.00. On average, they predict the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 263.2% from the stock's current price.
View analysts price targets for INZY
or view top-rated stocks among Wall Street analysts.

How have INZY shares performed in 2024?

Inozyme Pharma's stock was trading at $4.26 on January 1st, 2024. Since then, INZY shares have increased by 9.9% and is now trading at $4.68.
View the best growth stocks for 2024 here

When is Inozyme Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our INZY earnings forecast

How were Inozyme Pharma's earnings last quarter?

Inozyme Pharma, Inc. (NASDAQ:INZY) announced its earnings results on Tuesday, March, 12th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.04.

What other stocks do shareholders of Inozyme Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inozyme Pharma investors own include Procter & Gamble (PG), RTX (RTX), Cisco Systems (CSCO), CSX (CSX), CVS Health (CVS), Home Depot (HD), Resideo Technologies (REZI), Thermo Fisher Scientific (TMO) and Abbott Laboratories (ABT).

When did Inozyme Pharma IPO?

Inozyme Pharma (INZY) raised $75 million in an IPO on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Inozyme Pharma's major shareholders?

Inozyme Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Affinity Asset Advisors LLC (4.27%), Vanguard Group Inc. (3.91%), Kennedy Capital Management LLC (0.71%), GSA Capital Partners LLP (0.21%), SG Americas Securities LLC (0.02%) and California State Teachers Retirement System (0.01%). Insiders that own company stock include Axel Bolte, Douglas A Treco, Henric Bjorn Bjarke, Longitude Capital Partners Iii, Pivotal Bioventure Partners Fu and Robert Lorne Hopfner.
View institutional ownership trends

How do I buy shares of Inozyme Pharma?

Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INZY) was last updated on 5/23/2024 by Staff

From Our Partners